Transanal minimally invasive surgery (TAMIS) versus endoscopic submucosal dissection (ESD) for resection of non-pedunculated rectal lesions (TRIASSIC study): study protocol of a European multicenter randomised controlled trial.


Journal

BMC gastroenterology
ISSN: 1471-230X
Titre abrégé: BMC Gastroenterol
Pays: England
ID NLM: 100968547

Informations de publication

Date de publication:
13 Jul 2020
Historique:
received: 03 04 2020
accepted: 02 07 2020
entrez: 15 7 2020
pubmed: 15 7 2020
medline: 15 5 2021
Statut: epublish

Résumé

In the recent years two innovative approaches have become available for minimally invasive en bloc resections of large non-pedunculated rectal lesions (polyps and early cancers). One is Transanal Minimally Invasive Surgery (TAMIS), the other is Endoscopic Submucosal Dissection (ESD). Both techniques are standard of care, but a direct randomised comparison is lacking. The choice between either of these procedures is dependent on local expertise or availability rather than evidence-based. The European Society for Endoscopy has recommended that a comparison between ESD and local surgical resection is needed to guide decision making for the optimal approach for the removal of large rectal lesions in Western countries. The aim of this study is to directly compare both procedures in a randomised setting with regard to effectiveness, safety and perceived patient burden. Multicenter randomised trial in 15 hospitals in the Netherlands. Patients with non-pedunculated lesions > 2 cm, where the bulk of the lesion is below 15 cm from the anal verge, will be randomised between either a TAMIS or an ESD procedure. Lesions judged to be deeply invasive by an expert panel will be excluded. The primary endpoint is the cumulative local recurrence rate at follow-up rectoscopy at 12 months. Secondary endpoints are: 1) Radical (R0-) resection rate; 2) Perceived burden and quality of life; 3) Cost effectiveness at 12 months; 4) Surgical referral rate at 12 months; 5) Complication rate; 6) Local recurrence rate at 6 months. For this non-inferiority trial, the total sample size of 198 is based on an expected local recurrence rate of 3% in the ESD group, 6% in the TAMIS group and considering a difference of less than 6% to be non-inferior. This is the first European randomised controlled trial comparing the effectiveness and safety of TAMIS and ESD for the en bloc resection of large non-pedunculated rectal lesions. This is important as the detection rate of these adenomas is expected to further increase with the introduction of colorectal screening programs throughout Europe. This study will therefore support an optimal use of healthcare resources in the future. Netherlands Trial Register, NL7083 , 06 July 2018.

Sections du résumé

BACKGROUND BACKGROUND
In the recent years two innovative approaches have become available for minimally invasive en bloc resections of large non-pedunculated rectal lesions (polyps and early cancers). One is Transanal Minimally Invasive Surgery (TAMIS), the other is Endoscopic Submucosal Dissection (ESD). Both techniques are standard of care, but a direct randomised comparison is lacking. The choice between either of these procedures is dependent on local expertise or availability rather than evidence-based. The European Society for Endoscopy has recommended that a comparison between ESD and local surgical resection is needed to guide decision making for the optimal approach for the removal of large rectal lesions in Western countries. The aim of this study is to directly compare both procedures in a randomised setting with regard to effectiveness, safety and perceived patient burden.
METHODS METHODS
Multicenter randomised trial in 15 hospitals in the Netherlands. Patients with non-pedunculated lesions > 2 cm, where the bulk of the lesion is below 15 cm from the anal verge, will be randomised between either a TAMIS or an ESD procedure. Lesions judged to be deeply invasive by an expert panel will be excluded. The primary endpoint is the cumulative local recurrence rate at follow-up rectoscopy at 12 months. Secondary endpoints are: 1) Radical (R0-) resection rate; 2) Perceived burden and quality of life; 3) Cost effectiveness at 12 months; 4) Surgical referral rate at 12 months; 5) Complication rate; 6) Local recurrence rate at 6 months. For this non-inferiority trial, the total sample size of 198 is based on an expected local recurrence rate of 3% in the ESD group, 6% in the TAMIS group and considering a difference of less than 6% to be non-inferior.
DISCUSSION CONCLUSIONS
This is the first European randomised controlled trial comparing the effectiveness and safety of TAMIS and ESD for the en bloc resection of large non-pedunculated rectal lesions. This is important as the detection rate of these adenomas is expected to further increase with the introduction of colorectal screening programs throughout Europe. This study will therefore support an optimal use of healthcare resources in the future.
TRIAL REGISTRATION BACKGROUND
Netherlands Trial Register, NL7083 , 06 July 2018.

Identifiants

pubmed: 32660488
doi: 10.1186/s12876-020-01367-z
pii: 10.1186/s12876-020-01367-z
pmc: PMC7359465
doi:

Types de publication

Clinical Trial Protocol Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

225

Subventions

Organisme : ZonMw
ID : 852001926

Références

Int J Colorectal Dis. 2005 Mar;20(2):126-36
pubmed: 15449078
Gut. 2018 Nov;67(11):1965-1973
pubmed: 28988198
J Comput Assist Tomogr. 2011 Sep-Oct;35(5):531-4
pubmed: 21926843
Ann Surg Oncol. 2009 May;16(5):1255-65
pubmed: 19219506
Gut. 2018 May;67(5):837-846
pubmed: 28659349
Gastroenterology. 2017 Sep;153(3):732-742.e1
pubmed: 28583826
Surg Endosc. 2020 Mar;34(3):1025-1034
pubmed: 31754850
Eur J Surg Oncol. 2009 Dec;35(12):1280-5
pubmed: 19487099
Surg Endosc. 2020 Apr;34(4):1688-1695
pubmed: 31292744
N Engl J Med. 2012 Feb 23;366(8):687-96
pubmed: 22356322
Surg Endosc. 2010 Sep;24(9):2200-5
pubmed: 20174935
Tech Coloproctol. 2014 Sep;18(9):775-88
pubmed: 24848524
BMC Surg. 2009 Mar 13;9:4
pubmed: 19284647
Gut. 2018 Sep;67(9):1745-1746
pubmed: 29055907
Eur Radiol. 2007 Feb;17(2):379-89
pubmed: 17008990
Endoscopy. 2017 Mar;49(3):270-297
pubmed: 28212588
Qual Life Res. 2016 Jul;25(7):1853-8
pubmed: 26711791
Surg Endosc. 2010 Feb;24(2):343-52
pubmed: 19517168
Am Surg. 2015 Mar;81(3):273-7
pubmed: 25760203
Surg Endosc. 2012 Aug;26(8):2220-30
pubmed: 22278105
Gastroenterology. 2011 Jun;140(7):1909-18
pubmed: 21392504
Clin Gastroenterol Hepatol. 2007 Jun;5(6):678-83; quiz 645
pubmed: 17466600
Surg Endosc. 2014 Feb;28(2):427-38
pubmed: 24149849
Adv Exp Med Biol. 2016;908:161-81
pubmed: 27573772

Auteurs

Nik Dekkers (N)

Department of Gastroenterology & Hepatology, Leiden University Medical Center, Albinusdreef 2, 2333 ZA, Leiden, The Netherlands. n.dekkers@lumc.nl.

Jurjen J Boonstra (JJ)

Department of Gastroenterology & Hepatology, Leiden University Medical Center, Albinusdreef 2, 2333 ZA, Leiden, The Netherlands.

Leon M G Moons (LMG)

Department of Gastroenterology & Hepatology, University Medical Center Utrecht, Utrecht, The Netherlands.

Roel Hompes (R)

Department of Surgery, Amsterdam University Medical Center, Amsterdam, The Netherlands.

Barbara A Bastiaansen (BA)

Department of Gastroenterology & Hepatology, Amsterdam University Medical Center, Amsterdam, The Netherlands.

Jurriaan B Tuynman (JB)

Department of Surgery, Amsterdam University Medical Center, Amsterdam, The Netherlands.

Arjun D Koch (AD)

Department of Gastroenterology & Hepatology, Erasmus Medical Center, Rotterdam, The Netherlands.

Bas L A M Weusten (BLAM)

Department of Gastroenterology & Hepatology, St. Antonius Hospital, Nieuwegein, The Netherlands.

Apollo Pronk (A)

Department of Surgery, Diakonessenhuis, Utrecht, The Netherlands.

Peter A Neijenhuis (PA)

Department of Surgery, Alrijne hospital, Leiderdorp, The Netherlands.

Marinke Westerterp (M)

Department of Surgery, Haaglanden Medical Center, The Hague, The Netherlands.

Wilbert B van den Hout (WB)

Department of Medical Decision Making & Quality of Care, Leiden University Medical Center, Leiden, The Netherlands.

Alexandra M J Langers (AMJ)

Department of Gastroenterology & Hepatology, Leiden University Medical Center, Albinusdreef 2, 2333 ZA, Leiden, The Netherlands.

Jolein van der Kraan (J)

Department of Gastroenterology & Hepatology, Leiden University Medical Center, Albinusdreef 2, 2333 ZA, Leiden, The Netherlands.

Alaa Alkhalaf (A)

Department of Gastroenterology & Hepatology, Isala hospital, Zwolle, The Netherlands.

Jonathan Y L Lai (JYL)

Department of Gastroenterology & Hepatology, Haaglanden Medical Center, The Hague, The Netherlands.

Frank Ter Borg (F)

Department of Gastroenterology & Hepatology, Deventer Hospital, Deventer, The Netherlands.

Hans Fabry (H)

Department of Surgery, Bravis Hospital, Bergen op Zoom, The Netherlands.

Eric Halet (E)

Department of Gastroenterology & Hepatology, Bravis Hospital, Bergen op Zoom, The Netherlands.

Matthijs P Schwartz (MP)

Departmet of Gastroenterology & Hepatology, Meander Medical Center, Amersfoort, The Netherlands.

Wouter B Nagengast (WB)

Department of Gastroenterology & Hepatology, University Medical Center Groningen, Groningen, The Netherlands.

Jan Willem A Straathof (JWA)

Department of Gastroenterology & Hepatology, Maastricht University Medical Center, Maastricht, The Netherlands.

Rogier W R Ten Hove (RWR)

Department of Gastroenterology & Hepatology, Alrijne Hospital, Leiderdorp, The Netherlands.

Leendert H Oterdoom (LH)

Department of Gastroenterology & Hepatology, Hagaziekenhuis, The Hague, The Netherlands.

Christiaan Hoff (C)

Department of Surgery, Medical Center Leeuwarden, Leeuwarden, The Netherlands.

Eric J Th Belt (EJT)

Department of Surgery, Albert Schweitzer Hospital, Dordrecht, The Netherlands.

David D E Zimmerman (DDE)

Department of Surgery, Elisabeth-TweeSteden Ziekenhuis, Eindhoven, The Netherlands.

Muhammed Hadithi (M)

Department of Gastroenterology & Hepatology, Maasstad Hospital, Rotterdam, The Netherlands.

Hans Morreau (H)

Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands.

Erienne M V de Cuba (EMV)

Pathan B.V. - Pathology Laboratorium, Rotterdam, The Netherlands.

Jeroen W A Leijtens (JWA)

Department of Surgery, Laurentius Hospital, Roermond, The Netherlands.

Hans F A Vasen (HFA)

Department of Gastroenterology & Hepatology, Leiden University Medical Center, Albinusdreef 2, 2333 ZA, Leiden, The Netherlands.

Monique E van Leerdam (ME)

Department of Gastroenterology & Hepatology, Leiden University Medical Center, Albinusdreef 2, 2333 ZA, Leiden, The Netherlands.
Department of Gastroenterology and Hepatology, Netherlands Cancer Institute, Amsterdam, The Netherlands.

Eelco J R de Graaf (EJR)

Department of Surgery, IJsselland Hospital, Capelle aan den IJssel, The Netherlands.

Pascal G Doornebosch (PG)

Department of Surgery, IJsselland Hospital, Capelle aan den IJssel, The Netherlands.

James C H Hardwick (JCH)

Department of Gastroenterology & Hepatology, Leiden University Medical Center, Albinusdreef 2, 2333 ZA, Leiden, The Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH